Relay Therapeutics, Inc. (RLAY)

Market Cap	1.81B +234.1%
Revenue (ttm)	15.36M +53.4%
Net Income	-276.48M
EPS	-1.61
Shares Out	178.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	523,461
Open	9.80
Previous Close	9.93
Day's Range	9.66 - 10.03
52-Week Range	1.78 - 11.49
Beta	1.62
Analysts	Strong Buy
Price Target	16.14 (+59.64%)
Earnings Date	May 4, 2026

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases. It also develops R...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 16, 2020
• Employees: 192
• Stock Exchange: NASDAQ
• Ticker Symbol: RLAY
• Website: https://www.relaytx.com

Financial Performance

In 2025, Relay Therapeutics's revenue was $15.36 million, an increase of 53.44% compared to the previous year's $10.01 million. Losses were -$276.48 million, -18.13% less than in 2024.

Analyst Summary

According to 7 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price target is $16.14, which is an increase of 59.64% from the latest price.

Price Target

$16.14

(59.64% upside)

Analyst Consensus: Strong Buy